Management of hepatitis B: Pakistan Society for the Study of Liver Diseases (PSSLD) practice guidelines

Journal of the College of Physicians and Surgeons Pakistan

Volumn 20, Issue 3, 2010, Pages 198-201

  Abbas, Zaigham ^a   Jafri, Wasim ^b   Hamid, Saeed ^b  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

Author keywords

Analogues; Hepatitis B; Interferon alpha; Nucleoside; Nucleotide; Treatment guidelines

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; TELBIVUDINE; TENOFOVIR; THYMOSIN; VIRUS DNA;

ADD ON THERAPY; ARTICLE; DELTA AGENT HEPATITIS; DISEASE RESISTANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MIXED INFECTION; PAKISTAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREVALENCE; RISK FACTOR; SCREENING; SEROCONVERSION; TREATMENT RESPONSE;

ALANINE TRANSAMINASE; ALGORITHMS; DNA, VIRAL; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS;

EID: 77950488514     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Abbas Z, Jafri W, Shah SHA, Khokhar N, Zuberi SJ; Members of the Consensus Panel. PSG Consensus Statement on management of Hepatitis B virus infection-2003. J Pak Med Assoc 2004; 54:150-158
2. Ali SA, Donahue RM, Qureshi H, Vermund SH. Hepatitis B and Hepatitis C in Pakistan: prevalence and risk factors. Int J Infect Dis 2009; 13:9-19. Epub 2008 Oct 2.
3. Yusuf MA, Badar F, Meerza F, Khokhar RA, Ali FA, Sarwar S, et al. Survival from hepatocellular carcinoma at a cancer hospital in Pakistan. Asian Pac J Cancer Prev 2007; 8:272-274
4. Qureshi H. Prevalence of Hepatitis B and C in Pakistan-1st Population Based Survey. 2nd Annual Meeting of Pakistan Society for the study of liver diseases: Karachi; 2008.
5. Saeeda B, Siddiqui AA, Chakravarty R, Moatter T, Unnissa T, Nazr-ul-Hasnain. Phylogenetic analysis of Hepatitis B virus in Pakistan. J Coll Physicians Surg Pak 2008; 18:688-694
6. Abbas Z, Muzaffar R, Siddiqui A, Naqvi SA, Rizvi SA. Genetic variability in the precore and core promoter regions of Hepatitis B virus strains in Karachi. BMC Gastroenterol 2006; 6:20.
7. Jafri W, Jafri N, Yakoob J, Islam M, Tirmizi SFA, Jafar T, et al. Hepatitis B and C: prevalence and risk factors associated with seropositivity among children in Karachi, Pakistan. BMC Infect Dis 2006; 6:101.
8. Aziz S, Muzaffar R, Hafiz S, Abbas Z, Zafar MN, Naqvi SA, et al. Helicobacter pylori, Hepatitis viruses A, C, E antibodies and HBsAg - prevalence and associated risk factors in paediatric communities of Karachi. J Coll Physicians Surg Pak 2007; 17:195-198
9. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han K, et al. Asian-Pacific consensus statement on the management of chronic Hepatitis B: a 2008 update. Hepatol Int 2008; 2:263-283
10. Lok AS, McMahon BJ. AASLD practice guidelines: chronic Hepatitis B. Hepatology 2007; 45:507-539
11. Keeffe EB, Zeuzem S, Koff RS, Dieterich DT, Esteban-Mur R, Gane EJ, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic Hepatitis B. Clin Gastroenterol Hepatol 2007; 5:890-897 Epub 2007 Jul 13.
12. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic Hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008; 6:1315-1341 Epub 2008 Aug 23.
13. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic Hepatitis B. J Hepatol 2009; 50:227-42.
14. Epub 2008 Oct 29. Comment in: J Hepatol 2009; 51:224-226
15. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh II. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328:983.
16. Brunetto MR, Oliveri F, Coco B, Leandro G, Colombatto P, Gorin JM, et al. Outcome of anti-HBe positive chronic Hepatitis B in alpha-interferon treated and untreated patients: a long-term cohort study. J Hepatol 2002; 36:263-270
17. Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, et al. Re-evaluation of serum alanine aminotransferase upper normal limit and its modulating factors in a large-scale population study. Liver Int 2006; 26:445-50.
18. Comment in: Liver Int 2006; 26:1155-1156
19. Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic Hepatitis B: a case-control study. Aliment Pharmacol Ther 2007; 26:377-382
20. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Risk evaluation of viral load elevation and associated liver disease/cancer-In HBV (the REVEAL-HBV) study group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86. Comment in: p. 898-991
21. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al; Reveal-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum Hepatitis B virus DNA level. JAMA 2006; 295:65-73.
22. Papatheodoridis GV, Manolakopoulos S, Archimandritis AJ. Current treatment indications and strategies in chronic Hepatitis B virus infection. World J Gastroenterol 2008; 14:6902-6910
23. Lai C, Yuen M. Chronic Hepatitis B: new goals, new treatment. N Engl J Med 2008; 359:2488-2491
24. Cheng PN, Chang TT. Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic Hepatitis B patients. Expert Rev Anti Infect Ther 2008; 6:569-579
25. Keeffe EB, Marcellin P. New and emerging treatment of chronic Hepatitis B. Clin Gastroenterol Hepatol 2007; 5:285-294 Epub 2007 Jan 9.
26. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic Hepatitis B for up to 5 years. Gastroenterology 2006; 131:1743-1751 Epub 2006 Sep 20.
27. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic Hepatitis B. N Engl J Med 2008; 359:2442-2455
28. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Globe Study Group. Telbuvidine versus lamivudine in patients with chronic Hepatitis B. N Engl J Med 2007; 357:2576-88.
29. Comment in: N Engl J Med 2008; 358:1517; author reply 1517-1518
30. Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33:998-1002.
31. Papatheodoridis GV, Deutsch M. Resistance issues in treating chronic Hepatitis B. Future Microbiol 2008; 3:525-538
32. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant Hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712
33. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant Hepatitis B patients. Gastroenterology 2007; 133:1445-1451
34. Liaw YF. Management of YMDD mutations during lamivudine therapy in patients with chronic Hepatitis B. J Gastroenterol Hepatol 2002; 17:S333-7.
35. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic Hepatitis B. Gastroenterology 2004; 126:91-101.
36. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing Hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int 2008; 28:28-38. Epub 2007 Nov 1.
37. Ni YH, Chang MH, Huang LM, Chen HL, Hsu HY, Chiu TY, et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass Hepatitis B vaccination. Ann Intern Med 2001; 135:796-800. Comment in: p. 835-836